EPR is critical to save the precious lives currently unrecoverable when CPR fails. EPR-Technologies utilizes the revolutionary emergency resuscitation capabilities developed by the Safar Center for the rapid induction of profound hypothermia (cooling down to 10°C or 50°F) to eliminate the body’s need for oxygen for three-plus (3+) hours during which time evacuation to a medical facility, surgical intervention and repairs, and then rewarming and resuscitation may occur.
The first ever human clinical trial is set to begin in 2013 shortly using trauma victims who do not respond to CPR because of massive bleeding. The clinical trial will begin at the University of Pittsburgh Medical Center and the University of Maryland Shock Trauma Center.
EPR-Technologies continues to pursue its plans to introduce specific, novel, emergency medical procedures and devices that will support the rapid use of profound hypothermia in victims unresponsive to CPR at the point of injury. The first basic EPR procedural patent will soon be awarded by the U.S. Patent Office.
EPR-Technologies have established a strong strategic relationship with ELVIE INTERNATIONAL CORPORATION (Las Vegas, Nevada) for all EPR product sales, marketing and distribution functions using
ELVIE’s International Distribution Medical Network. Additionally, following the EPR human clinical trial and FDA approval of EPR device prototypes, component manufacturing and assembly, to every extent possible, will be implemented and expanded at ELVIE’s manufacturing facilities in the United States, China, Southeast Asia, India, South America and Europe.